Frequent Continuous Glucose Monitoring Significantly Improves Glycemic Control in Type 2 Diabetes: JAMA Dr Riya Dave4 Nov 2025 9:00 AM ISTA new study published in JAMA Network Open has identified that frequent use of continuous glucose monitoring devices is strongly associated with...
Dapagliflozin and Sitagliptin FDC: Exploring Early Initiation Benefits In Young Newly Diagnosed T2D in India Dr. Rajiv Kovil1 Nov 2025 10:34 AM ISTType 2 diabetes (T2D) is a growing epidemic in India. India has 101 million people with diabetes and 136 million with prediabetes, with disease onset...
Explainer video: Assess- Evaluating Patient Readiness for Diabetes- Management Strategies Deeksha Bhandari31 Oct 2025 12:01 PM ISTDiscussing weight with people living with type 2 diabetes can be difficult, but it is vital to improving care. Many patients with overweight or...
DAa-ViNCI Study: Real-World Data shows Efficacy of Vildagliptin- Dapagliflozin FDC among High-CV Risk T2D in Indian Cardiology Settings Deeksha Bhandari13 Oct 2025 12:30 PM ISTDAa-ViNCI study which analyzed the efficacy, safety and practice of pattern of Vildagliptin 100mg and dapagliflozin 10mg in cardiology practice. ...
The Prediabetes Show Episode 3 - Tackling Patient Conversations around Prediabetes and Metformin Deeksha Bhandari28 Aug 2025 12:30 PM ISTAs we observe Prediabetes Month presenting episode 3rd of the prediabetes show we have Dr Nandini Rastogi, Diabetologist, Kanpur, India and Dr Aloke ...
Inhaled Insulin Shows Promise as Safe Option for diabetes management in Pregnancy: Study Dr. Shravani Dali24 Aug 2025 10:30 PM ISTA study published in Pregnancy suggests that inhaled technosphere insulin may be a safe alternative to rapid-acting insulin analogs for diabetes...
Mifepristone Significantly Lowers HbA1c in Type 2 Diabetes with Hypercortisolism: Study Dr Riya Dave28 Jun 2025 9:00 AM ISTResearchers have discovered in a randomized placebo-controlled trial that mifepristone (Korlym) led to a significant reduction in HbA1c levels in...
Micro Labs Launches Sitanorm-E, Sitagliptin-Empagliflozin FDC for Uncontrolled Type 2 Diabetes in India Deeksha Bhandari6 Jun 2025 12:11 PM ISTMicro Labs has announced the launch of Sitanorm-E, a fixed-dose combination (FDC) of Sitagliptin and Empagliflozin. The combination is formulated to...
USV Launches Empagliflozin Range Under Xenia Brand Deeksha Bhandari2 April 2025 12:23 PM ISTUSV Pvt. Ltd., a leader in diabetes care, has announced the launch of its Xenia brand range in India, following the patent expiry of Empagliflozin. ...
USV Expands Diabetes Portfolio with Cost-Effective Liralin-EP in India Deeksha Bhandari22 March 2025 1:00 PM ISTUSV Pvt. Ltd., launches the Liralin EP a combination of Linagliptin & Empagliflozin at just Rs 12.90 per tablet for strengthening it's affordable...
Spore-forming microbial whole-cell sensing strategy promising strategy against diabetes management: Study Jacinthlyn Sylvia8 March 2025 9:00 AM ISTA new study published in the journal of Nature Microsystems & Nanoengineering found that spore-forming microbial whole-cell sensing strategy to be...
AID beneficial and safe option for improving HbA1C among insulin-dependent type 2 diabetes patients: JAMA Dr Riya Dave20 Feb 2025 8:30 AM ISTA nonrandomized clinical trial found that HbA1c levels decreased in a diverse group of adults with type 2 diabetes after starting automated insulin...
